Literature DB >> 9804330

Localization of sphingomyelinase in lesional skin of atopic dermatitis patients.

S Kusuda1, C Y Cui, M Takahashi, T Tezuka.   

Abstract

Because it has been suggested that the majority of the activity hydrolysing [N-methyl-14C] sphingomyelin is due to sphingomyelin acylase in the lesional skins of atopic dermatitis (AD), in this study we used immunologic techniques to localize and quantitate sphingomyelinase in AD lesional and normal skin. A polyclonal antibody raised against a synthetic polypeptide corresponding to a portion of the amino acid sequence deduced from the cDNA of human acid sphingomyelinase, cross-reacted with a 58 kDa, pI 5.8 human epidermal protein in an immunoblot analysis. The 58 kDa protein-rich fraction, partially purified by immunoprecipitation, converted [N-methyl-14C]-sphingomyelin to 14C-phosphorylcholine and ceramides. The reaction products were immunohistochemically observed in the intercellular domain from the upper spinous cell layer to the upper stratum corneum cell layers in the lesional skin of AD patients. Immunoelectron-microscopically, gold particles appeared to be concentrated in the intercellular domains of the granular-upper stratum corneum cells in the lesional skin of AD patients. The total amount of the 58 kDa protein in a 7 mm2 area of the skin was measured by quantitative immunoblot analysis; and was slightly increased in the lesional skin samples [3.5 +/- 0.3 microg per 7 mm2 (n = 7)], as compared with the nonlesional skin samples of AD patients [2.8 +/- 0.19 microg per 7 mm2 (n = 10)] and with the normal skin samples [2.7 +/- 0.22 microg per 7 mm2 (n = 10)]. This difference (between the lesional skin of AD and the nonlesional skin of AD or the normal control) was significant (nonpaired student's t test, p < 0.05).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804330     DOI: 10.1046/j.1523-1747.1998.00370.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Skin barrier defects in atopic dermatitis.

Authors:  Rachana Agrawal; Judith A Woodfolk
Journal:  Curr Allergy Asthma Rep       Date:  2014-05       Impact factor: 4.806

2.  The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide.

Authors:  K Higuchi; J Hara; R Okamoto; M Kawashima; G Imokawa
Journal:  Biochem J       Date:  2000-09-15       Impact factor: 3.857

3.  Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.

Authors:  Yutaka Hatano; Mao-Qiang Man; Yoshikazu Uchida; Debra Crumrine; Theodora M Mauro; Kenneth R Feingold; Peter M Elias; Walter M Holleran
Journal:  J Allergy Clin Immunol       Date:  2009-10-08       Impact factor: 10.793

4.  Sphingomyelin Deacylase, the Enzyme Involved in the Pathogenesis of Atopic Dermatitis, Is Identical to the β-Subunit of Acid Ceramidase.

Authors:  Yasuhiro Teranishi; Hiroshi Kuwahara; Masaru Ueda; Tadashi Takemura; Masanori Kusumoto; Keiji Nakamura; Jun Sakai; Toru Kimura; Yasuji Furutani; Makoto Kawashima; Genji Imokawa; Mari Nogami-Itoh
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

Review 5.  Cutting Edge of the Pathogenesis of Atopic Dermatitis: Sphingomyelin Deacylase, the Enzyme Involved in Its Ceramide Deficiency, Plays a Pivotal Role.

Authors:  Genji Imokawa
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 6.  The Role of Sphingolipids Metabolism in Cancer Drug Resistance.

Authors:  Marina Bataller; Almudena Sánchez-García; Yoelsis Garcia-Mayea; Cristina Mir; Isabel Rodriguez; Matilde Esther LLeonart
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.